Cosmos Health Inc. (COSM) - Q3 2024 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. Cosmos Health Inc. is an international healthcare group headquartered in Thessaloniki, Greece, operating in the nutraceuticals, pharmaceuticals, and healthcare distribution sectors. The company is a Smaller Reporting Company and is currently listed on the Nasdaq Capital Market. As of November 14, 2024, there were 23,346,049 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q3 2024 (3 Months) | Q3 2023 (3 Months) | YTD 2024 (9 Months) | YTD 2023 (9 Months) |
|---|---|---|---|---|
| Revenue | $12,411,048 | $12,823,797 | $40,202,238 | $37,537,003 |
| Gross Profit | $1,206,862 | $1,214,758 | $3,307,736 | $3,118,669 |
| Gross Margin | 9.7% | 9.5% | 8.2% | 8.3% |
| Net Loss | $(2,182,534) | $(3,349,204) | $(6,639,935) | $(4,790,597) |
| Net Loss Attributable to Common Stockholders | $(8,377,558) | $(3,364,257) | $(12,834,959) | $(4,805,650) |
| EPS (Basic & Diluted) | $(0.45) | $(0.27) | $(0.72) | $(0.42) |
| Cash and Cash Equivalents | $3,314,845 | N/A | $3,314,845 | $2,360,604 |
| Working Capital | $11,027,653 | N/A | $11,027,653 | $12,285,310 |
| Total Debt (Notes & Lines of Credit) | $10,256,400 | N/A | $10,256,400 | $11,236,499 |
Note: Total Debt includes Lines of Credit ($5,989,425) and Notes Payable ($4,267,972). Net Loss Attributable to Common Stockholders includes significant non-cash "deemed dividends" related to warrant modifications.
Material Changes vs. Prior Period
- Revenue: Q3 2024 revenue decreased 3.2% compared to Q3 2023, primarily due to production delays at the Cana subsidiary and decreased nutraceutical sales by Decahedron. However, YTD revenue increased 7.1% driven by wholesale growth from the Bikas acquisition.
- Net Loss: Q3 2024 net loss improved (decreased) by 35.6% compared to Q3 2023. This improvement is largely due to the absence of significant one-time provisions for bad debt and tax liabilities recorded in the prior year. Conversely, YTD 2024 net loss increased by 38.6% compared to YTD 2023, primarily because the prior year included a $1.9M gain on debt extinguishment and a $1.6M bargain purchase gain from the Cana acquisition.
- Operating Expenses: General and administrative expenses decreased significantly in Q3 2024 ($1.78M vs $2.57M in Q3 2023) due to the lack of large provisions recorded in the prior year. Salaries and wages increased 5.2% in Q3 due to the full inclusion of Cana's payroll.
- Deemed Dividends: The company recorded a non-cash deemed dividend of $6.19M in Q3 2024 related to a warrant inducement transaction, significantly impacting the Net Loss Attributable to Common Stockholders.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: Management has expressed substantial doubt about the company's ability to continue as a going concern for the next twelve months. This is due to an accumulated deficit of $104.5M and revenues that do not yet sustain operations. The company relies on future capital raises, expense curtailment, and debt restructuring.
- Capital Raising: In September 2024, the company executed a warrant inducement, reducing the exercise price of 4.87M warrants from $1.45 to $0.8701, raising gross proceeds of $4.24M. The company plans to file an S-1 registration statement for up to $7.5M by November 2024.
- Nasdaq Compliance: On November 6, 2024, the company received a non-compliance letter from Nasdaq for failing to maintain a $1.00 minimum bid price. The company has 180 days to regain compliance, potentially via a reverse stock split.
- Acquisitions: The company completed the acquisition of Cloudscreen (AI drug repurposing platform) in January 2024 for $637,080. It also signed a distribution agreement with Pharmalink for the UAE market.
- Internal Controls: The company disclosed material weaknesses in internal controls, specifically regarding segregation of duties and IT General Controls. Remediation is planned for completion by December 31, 2024.
Investor Verification Checklist
- Going Concern Status: Verify the success of the planned $7.5M equity offering and the ability to secure additional debt financing to sustain operations.
- Nasdaq Listing: Monitor the stock price to ensure it meets the $1.00 minimum bid requirement or confirm the execution of a reverse stock split.
- Warrant Inducement Impact: Assess the dilution impact of the 9.75M new warrants issued and the 4.87M warrants with reduced exercise prices.
- Related Party Transactions: Review the significant balances with Doc Pharma (related party), including $6.4M in prepaid expenses and $2.4M in receivables.
- Internal Control Remediation: Confirm the timeline and effectiveness of the remediation plan for material weaknesses in financial reporting controls.